Saturday 17 October 2026 Export NBIX’s income statement to Excel — free account

Neurocrine Biosciences, Inc.

NBIX Healthcare Drug Manufacturers Specialty & Generic

Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024. In the quarter to June 2026, revenue grew 39.5%, EPS grew 31.2% and free cash flow grew 43.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five.

135.71 1.24 −0.91%

Follow NBIX

Alert me

Market cap: $13.9B
P/E: 19.2×
Fwd P/E: 30.5×
Dividend yield: —
F-score: 7/9
Altman Z: 7.80
Beneish M: −2.64
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

	Jun '26	Mar '26	Dec '25	Sep '25	Older periods
P/E ratio Full definition →	23.91	19.63	29.43	32.57	+8 more quarters Free account
P/S ratio Full definition →	5.05	4.27	4.93	5.20
P/FCF ratio Full definition →	19.56	15.93	18.85	23.53
P/Operating CF Full definition →	124.80	90.81	36.33	61.34
P/B ratio Full definition →	4.61	3.89	4.34	4.65
Price to Tangible BV Full definition →	17.60	3.90	4.35	4.70
EV/Sales Full definition →	5.09	4.02	4.61	4.99
EV/EBITDA Full definition →	20.65	15.48	20.71	24.19
EV/Operating CF Full definition →	19.14	14.45	16.85	21.03
EV/FCF Full definition →	19.74	15.01	17.61	22.58
Quick Ratio Full definition →	1.46	2.51	2.92	2.89
Current Ratio Full definition →	1.87	2.93	3.39	3.38
Net Debt/EBITDA Full definition →	(2.17)	(6.56)	(7.20)	(4.52)
Debt/Assets Full definition →	0.00%	0.00%	0.00%	0.00%
Debt/Equity Full definition →	0.00	0.00	0.00	0.00
Asset Turnover Full definition →	0.73	0.72	0.69	0.69
Operating CF/Net income Full definition →	0.94	0.74	2.53	1.09
Capex/Depreciation Full definition →	(0.28)	(1.25)	(0.46)	(1.71)
Interest Coverage Full definition →	52.24	—	—	—
Research and Development Expense of Revenue Full definition →	34.07%	36.37%	32.05%	31.45%
Selling, General and Administrative Expense of Revenue Full definition →	45.85%	39.10%	37.47%	36.68%
Intangible Assets out of Total Assets Full definition →	0.51	0.00	0.00	0.01
Share Based Compensation of Revenue Full definition →	6.78%	7.02%	7.27%	6.76%
Graham Net Nets Full definition →	0.00	0.07	0.08	0.06
Graham Number Full definition →	76.16	71.55	59.55	54.13
Earnings Yield Full definition →	4.18%	5.09%	3.40%	3.07%
Free Cash Flow Yield Full definition →	5.11%	6.28%	5.31%	4.25%
Revenue per Share Full definition →	9.50	8.10	8.10	8.00
Operating CF per Share Full definition →	1.35	1.45	3.90	2.29
Capex per Share Full definition →	(0.08)	(0.09)	0.02	(0.13)
Free Cash Flow per Share Full definition →	1.27	1.36	3.93	2.16
Cash per Share Full definition →	3.86	13.10	14.88	11.22
Shareholders Equity per Share Full definition →	36.57	33.90	32.69	30.22
Interest Debt per Share Full definition →	0.00	0.00	0.00	0.00
Book value per Share Full definition →	36.57	33.90	32.69	30.22
Free Cash Flow Full definition →	128.60	136.70	390.80	214.30
Working Capital Full definition →	763.00	1,604.40	1,779.30	1,520.40
Capital Expenditures Full definition →	(7.80)	(9.10)	2.40	(13.20)
Net Current Asset Value Full definition →	(28.00)	937.30	1,144.30	896.30
EV/EBIT Full definition →	21.62	15.82	21.30	24.34
Capex to Sales Full definition →	0.01	0.01	0.00	0.02
Price to Operating Income Full definition →	21.42	16.78	22.79	25.36
Other line items
Average Receivables Full definition →	741.35	642.05	582.95	604.55
Average Payables Full definition →	648.90	624.10	567.95	488.50
Average Inventory Full definition →	80.55	61.80	63.20	57.55
Average Assets Full definition →	4,624.45	4,296.95	4,175.10	3,900.35
Average Common Equity Full definition →	3,193.95	2,971.55	2,921.40	2,861.25

Show all line items

Columns are period end dates

Stockrow Weekly